Elanco Swings to Q3 Loss Amidst Divestiture Absence, Revenue Up 10%

Ticker: ELAN · Form: 10-Q · Filed: 2025-11-05T00:00:00.000Z

Sentiment: mixed

Topics: Animal Health, Pharmaceuticals, Q3 Earnings, Net Loss, Revenue Growth, Divestiture Impact, Debt Management

Related Tickers: ELAN, MRK

TL;DR

**ELAN's Q3 net loss is a red flag, despite revenue growth; the market will punish the lack of a one-time gain.**

AI Summary

Elanco Animal Health Inc. reported a net loss of $34 million for the three months ended September 30, 2025, a significant decline from the net income of $364 million in the same period of 2024. This shift was primarily driven by the absence of a $640 million gain on divestiture recognized in Q3 2024. Revenue increased by 10.4% to $1,137 million in Q3 2025 from $1,030 million in Q3 2024, with Pet Health revenue growing 9.7% to $533 million and Farm Animal revenue increasing 11.9% to $593 million. For the nine months ended September 30, 2025, net income was $44 million, down from $346 million in the prior year, while revenue rose 4.4% to $3,571 million. Key business changes include the sale of the aqua business in July 2024 and an agreement in May 2025 to sell certain future royalty revenues for $295 million in cash. Risks highlighted include operating in a highly competitive industry, dependence on top products, and the impact of substantial indebtedness. The strategic outlook focuses on continued growth in Pet Health and Farm Animal segments, despite the recent net loss.

Why It Matters

Elanco's swing to a net loss of $34 million in Q3 2025, compared to a $364 million net income in Q3 2024, is a critical signal for investors, largely due to the non-recurrence of a significant divestiture gain. While revenue growth of 10.4% to $1,137 million is positive, the underlying profitability concerns, especially with increased operating expenses, could impact investor confidence and future stock performance. Employees might face pressure for efficiency as the company navigates profitability challenges. Customers could see continued product innovation, particularly in the growing Pet Health segment, but competitive pressures from generic products remain a factor. In the broader animal health market, Elanco's performance reflects the ongoing consolidation and strategic asset management within the highly competitive industry.

Risk Assessment

Risk Level: medium — The risk level is medium due to a significant net loss of $34 million in Q3 2025, a stark contrast to the $364 million net income in Q3 2024, primarily driven by the absence of a $640 million gain on divestiture. While revenue increased by 10.4% to $1,137 million, the company's substantial indebtedness and reliance on top products, as noted in the risk factors, present ongoing financial vulnerabilities.

Analyst Insight

Investors should scrutinize Elanco's core operational profitability excluding one-time gains and monitor debt reduction strategies. Consider holding if the revenue growth trend continues and management outlines a clear path to sustainable net income, but be prepared to sell if operating expenses continue to outpace revenue growth.

Financial Highlights

debt To Equity
0.58
revenue
$1,137M
operating Margin
N/A
total Assets
$13,551M
total Debt
$4,024M
net Income
$(34)M
eps
$(0.07)
gross Margin
53.4%
cash Position
$505M
revenue Growth
+10.4%

Revenue Breakdown

SegmentRevenueGrowth
Pet Health$533M+9.7%
Farm Animal$593M+11.9%

Key Numbers

Key Players & Entities

FAQ

Why did Elanco Animal Health Inc. report a net loss in Q3 2025?

Elanco Animal Health Inc. reported a net loss of $34 million for the three months ended September 30, 2025, primarily because it did not have the $640 million gain on divestiture that boosted its net income to $364 million in the same period of 2024.

How did Elanco's revenue perform in Q3 2025?

Elanco's revenue increased by 10.4% to $1,137 million for the three months ended September 30, 2025, up from $1,030 million in Q3 2024. Both Pet Health and Farm Animal segments contributed to this growth.

What were the key drivers of revenue growth for Elanco in Q3 2025?

Key drivers of revenue growth for Elanco in Q3 2025 included a 9.7% increase in Pet Health revenue to $533 million and an 11.9% increase in Farm Animal revenue to $593 million, compared to the same period in 2024.

What significant business changes did Elanco undertake in 2024 and 2025?

In July 2024, Elanco sold its aqua business to a subsidiary of Merck Animal Health. In May 2025, the company entered into an agreement to sell certain qualifying royalties and other potential future cash flows for $295 million in cash.

What are the main risks highlighted in Elanco's 10-Q filing?

The main risks highlighted include operating in a highly competitive industry, dependence on the success of top products, the impact of substantial indebtedness on business operations, and changes in interest rates that could adversely affect earnings and cash flows.

How did Elanco's cash flow from operating activities change in the first nine months of 2025?

Net cash provided by operating activities for Elanco increased to $452 million for the nine months ended September 30, 2025, up from $364 million in the same period of 2024, despite the lower net income.

What is Elanco's current long-term debt position?

As of September 30, 2025, Elanco's long-term debt and finance lease liability stood at $3,962 million, a decrease from $4,277 million reported on December 31, 2024.

What is the impact of the new FASB accounting pronouncements on Elanco?

Elanco is currently assessing the impact of ASU 2023-09 (Income Taxes) and ASU 2024-03 (Expense Disaggregation Disclosures). ASU 2023-09 is expected to result in additional income tax disclosures, while ASU 2024-03 will provide more detailed information about significant expense categories.

How much did Elanco spend on research and development in Q3 2025?

Elanco's research and development expenses were $89 million for the three months ended September 30, 2025, a slight increase from $87 million in the same period of 2024.

What was Elanco's total equity as of September 30, 2025?

Elanco's total equity as of September 30, 2025, was $6,749 million, an increase from $6,096 million reported on December 31, 2024.

Risk Factors

Industry Context

Elanco operates in the animal health industry, which is characterized by intense competition from both large multinational corporations and smaller specialized firms. Key trends include increasing demand for pet care products and services, driven by humanization of pets, and a focus on sustainable and efficient food production in the farm animal segment. The industry is also influenced by advancements in veterinary medicine, biotechnology, and evolving regulatory landscapes regarding animal welfare and drug use.

Regulatory Implications

The animal health industry is subject to stringent regulatory oversight from bodies like the FDA and EMA, governing product approval, manufacturing standards, and marketing. Changes in regulations, particularly concerning antibiotic use in food-producing animals, can significantly impact product portfolios and market access for companies like Elanco.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Gain on divestiture
Profit realized from selling a business unit or asset. This is a non-recurring item that can significantly impact net income in a specific period. (The absence of a $640 million gain on divestiture in Q3 2025, compared to its presence in Q3 2024, is the primary driver for the year-over-year net income decline.)
Amortization of intangible assets
The systematic allocation of the cost of an intangible asset over its useful life. This is a non-cash expense that reduces net income. (A significant expense for Elanco, totaling $140 million in Q3 2025 and $404 million for the nine months ended September 30, 2025, impacting profitability.)
Liability for sale of future revenue
A financial obligation recorded when a company sells the rights to receive future revenue streams for an upfront payment. (Elanco recorded a $300 million liability related to the agreement to sell future royalty revenues, impacting its balance sheet.)
Other comprehensive (loss) income
Unrealized gains or losses on certain investments and foreign currency translations that are not included in net income but are reported separately. (Includes significant foreign currency translation gains ($626M for nine months ended Sep 30, 2025) and cash flow hedge losses, affecting total comprehensive income.)
Goodwill
An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. (A substantial asset on Elanco's balance sheet ($4.764 billion as of September 30, 2025), reflecting past acquisitions.)
Weighted-average shares outstanding
The average number of shares of common stock outstanding during a period, adjusted for the timing of share issuances or repurchases. (Used to calculate earnings per share (EPS). Basic weighted-average shares outstanding were 496.8 million for Q3 2025.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Elanco reported a significant swing from a net income of $364 million to a net loss of $34 million, primarily due to the absence of a $640 million gain on divestiture in Q3 2024. Despite this, revenue saw a healthy increase of 10.4% to $1.137 billion, driven by strong performance in both Pet Health (+9.7%) and Farm Animal (+11.9%) segments. Operating margins are not directly comparable due to the divestiture gain, but gross profit increased, indicating underlying operational strength. Key risks remain, including competitive pressures and substantial debt, though long-term debt has decreased.

Filing Stats: 4,748 words · 19 min read · ~16 pages · Grade level 18.2 · Accepted 2025-11-05 09:06:32

Filing Documents

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) 4 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (UNAUDITED) 5 CONDENSED CONSOLIDATED BALANCE SHEETS 6 CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) 7 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) 8 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 9 Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OVERVIEW 21 RESULTS OF OPERATIONS 23 SUMMARY OF CHANGES 23 LIQUIDITY AND CAPITAL RESOURCES 27

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 29

CONTROLS AND PROCEDURES

Item 4. CONTROLS AND PROCEDURES 29

. Other Information

PART II . Other Information Item 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 30 Item 1A.

RISK FACTORS

RISK FACTORS 30 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 30

DEFAULTS UPON SENIOR SECURITIES

Item 3. DEFAULTS UPON SENIOR SECURITIES 30

MINE SAFETY DISCLOSURES

Item 4. MINE SAFETY DISCLOSURES 30

OTHER INFORMATION

Item 5. OTHER INFORMATION 30 Item 6. EXHIBITS 31

SIGNATURES

SIGNATURES 32 2025 Q3 Form 10-Q | 1 Table of Contents

FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY

FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY This Quarterly Report on Form 10-Q (Form 10-Q) includes forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements concerning the impact on Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us or our) caused by the integration of business acquisitions, expected synergies and cost savings, product launches, global macroeconomic conditions, expectations relating to liquidity and sources of capital, our expected compliance with debt covenants, cost savings, expenses and reserves relating to restructuring actions, our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including but not limited to the following: operating in a highly competitive industry; the success of our research and development (R&D), regulatory approval and licensing efforts; the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein; competition from generic products that may be

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Elanco Animal Health Incorporated Condensed Consolidated Statements of Operations (Unaudited) (in millions, except per-share data) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue $ 1,137 $ 1,030 $ 3,571 $ 3,419 Cost of sales 530 492 1,567 1,502 Gross profit 607 538 2,004 1,917 Research and development 89 87 275 263 Marketing, selling and administrative 351 323 1,092 1,014 Amortization of intangible assets 140 133 404 397 Asset impairment, restructuring and other special charges 25 17 35 143 Gain on divestiture — ( 640 ) — ( 640 ) Interest expense, net of capitalized interest 52 58 140 189 Other expense , net — 1 23 12 (Loss) income before income taxes ( 50 ) 559 35 539 Income tax (benefit) expense ( 16 ) 195 ( 9 ) 193 Net (loss) income $ ( 34 ) $ 364 $ 44 $ 346 (Loss) earnings per share: Basic $ ( 0.07 ) $ 0.74 $ 0.09 $ 0.70 Diluted $ ( 0.07 ) $ 0.73 $ 0.09 $ 0.70 Weighted-average shares outstanding: Basic 496.8 494.3 496.2 493.9 Diluted 496.8 497.7 501.2 496.9 See accompanying notes to condensed consolidated financial statements. 2025 Q3 Form 10-Q | 4 Table of Contents Elanco Animal Health Incorporated Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) (in millions) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net (loss) income $ ( 34 ) $ 364 $ 44 $ 346 Other comprehensive (loss) income: Cash flow hedges, net of taxes ( 10 ) ( 81 ) ( 55 ) ( 58 ) Foreign currency translation, net of taxes 5 283 626 ( 10 ) Defined benefit plans, net of taxes ( 2 ) 1 1 ( 5 ) Other comprehensive (loss) income, net of taxes ( 7 ) 203 572 ( 73 ) Comprehensive (loss) income $ ( 41 ) $ 567 $ 616 $ 273 See accompanying notes to condensed consolidated financial statements. 2025 Q3 Form 10-Q | 5 Table of Contents Elanco Animal Health Incorporated Condensed Consolidated Balance Sheets (in millions

View on Read The Filing